{"entity":{"id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","aka":["RESTORE"],"tldr":"A phase 2 trial of NanO2TM in glioma & glioblastoma, run by NuvOx LLC, active and no longer recruiting.","summary":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM is a phase 2 interventional study registered as NCT03862430 by NuvOx LLC, with 87 participants enrolled, started 2023-03-31 and due to reach its primary completion in 2027-06-30. Interventions recorded: NanO2TM and Placebo Saline Infusion.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03862430","url":"https://clinicaltrials.gov/study/NCT03862430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03862430","phase":"2","setting":"A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE","sponsor":"NuvOx LLC","started":"2023-03-31","startedType":"actual","enrolled":87,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03862430/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}